問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

Recruiting

List

694Cases

2019-05-01 - 2022-12-31

Phase II/III

A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (Erlotinib or Gefitinib), as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Test Drug

    AZD3759

Participate Sites
4Sites

Recruiting4Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2021-10-15 - 2022-06-09

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-11-30 - 2024-07-31

Phase III

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
9Sites

Recruiting9Sites

2020-04-01 - 2024-01-10

Phase III

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
6Sites

Recruiting6Sites

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

2014-07-15 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

  • Condition/Disease

    NA

  • Test Drug

    ARN-509; softgel capsule

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2021-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-10-01 - 2030-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Rilvegostomig

Participate Sites
8Sites

Recruiting8Sites

1 66 67 68 69 70
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB